Join Our June Advocacy Challenge
Ask Congress to support the Supplemental Oxygen Access Reform Act in our June advocacy challenge.
Get involved
In the News
Discover the latest news from the Pulmonary Hypertension, including advocacy updates, research articles and event coverage.
Recent news
Dislaying 7 — 12 of 380
-
-
Discover Strategies To Balance PH and WorkJoin PHA 2026's Journeys lunch in Dallas to hear patient strategies for balancing careers and pulmonary hypertension.
Events
-
Help Continue PHA’s Mission Through a Giving SocietyDiscover PHA’s giving societies—donor support driving hope, progress, and lifesaving care for the pulmonary hypertension community.
Get involved
-
CEO Update: Share Your Trial Experiences for World PH DayAs World PHA Day approaches, please join PHA on May 5 to observe this important global event led by our partner PHA Europe. This year’s campaign, “Hope in Every Trial,” focuses on the importance of clinical trials and how trials can improve care for people with pulmonary hypertension.
News
-
Moms Advocate for Kids’ Oxygen Access
Two Cincinnati women work with their children’s PH care teams to promote better access to portable oxygen. The story originally appeared in the March 2026 issue of Pathlight magazine.
News
-
6 Reasons to Attend PHA 2026If you haven’t made up your mind to register for PHA 2026 International PH Conference and Scientific Sessions, discover these six must-attend general sessions.
News
PH in the News
Ralinepag shows delayed disease progression in PAH study
Ralinepag met a primary goal to delay disease progression in a Phase 3 study, United Therapeutics announced. The study met several secondary goals, including six-minute walk distance.
Read morePulmovant completes Phase 2 study enrollment for PH-ILD drug
Pulmovant has completed enrollment for its Phase 2 PHocus clinical trial to evaluate a once-daily inhaled treatment for PH-ILD. Mosliciguat helps widen blood vessels and could have anti-inflammatory and anti-fibrotic properties.
Read moreGossamer announces topline results from Phase 3 seralutinib study
Gossamer Bio’s Phase 3 seralutinib trial narrowly missed its primary endpoint goal to show improved six-minute walk distance at week 24, according to its news release. An unexpectedly large improvement in walk distance in the placebo group appeared in part to influence the outcome, Gossamer says. The company noted encouraging findings in key secondary goals, including reductions in NT-proBNP, improvements in clinical status and lower risk scores. The study also showed meaningful treatment effects in patients with intermediate and high-risk PH, Gossamer explains in a document for patients (pdf).
Read more